Plantar FasciitisNCT07785453
Serum CTGF in Chronic Plantar Fasciitis
An observational study of Plantar Fasciitis, run by Kanuni Sultan Suleyman Training and Research Hospital.
Trial summary
This observational study aims to evaluate serum Connective Tissue Growth Factor (CTGF/CCN2) levels in patients with chronic plantar fasciitis compared with asymptomatic controls. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Plantar Fasciitis
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 30 Aug 2026to 15 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults aged 18-65 years, including patients with chronic plantar fasciitis and asymptomatic controls without clinical or ultrasonographic findings of plantar fasciitis.
Who may be able to join
- Age 18-65 years.
- Written informed consent.
- For the patient group: chronic plantar heel pain for at least 3 months, pain during the first steps in the morning or after prolonged rest, tenderness over the medial calcaneal tubercle, and clinical and ultrasonographic findings consistent with chronic plantar fasciitis.
- For the control group: asymptomatic individuals without a previous diagnosis or clinical and ultrasonographic findings of plantar fasciitis.
Who cannot join
- Tarsal tunnel syndrome, calcaneal stress fracture, plantar fascia rupture, Achilles tendinopathy, heel fat pad syndrome, plantar fibromatosis, or other foot conditions causing plantar heel pain.
- Diabetes mellitus.
- Inflammatory rheumatic diseases or gout.
- Chronic kidney or liver disease.
- Malignancy.
- Active infection or autoimmune disease
Show all 10Show fewer
- Pregnancy.
- Previous foot or ankle surgery.
- Corticosteroid injection, platelet-rich plasma (PRP), prolotherapy, extracorporeal shock wave therapy (ESWT), or other interventional treatment to the affected heel within the previous 3 months.
- Serious systemic conditions that may affect serum CTGF/CCN2 levels.
About this study
Official title: Association of Serum Connective Tissue Growth Factor (CTGF/CCN2) Levels With Pain and Functional Status in Patients With Chronic Plantar Fasciitis
This observational study aims to evaluate serum Connective Tissue Growth Factor (CTGF/CCN2) levels in patients with chronic plantar fasciitis compared with asymptomatic controls. The study will also assess the associations between serum CTGF levels and clinical and ultrasonographic characteristics of chronic plantar fasciitis.
Read the detailed description
This is a single-center observational study including patients with chronic plantar fasciitis and asymptomatic controls. Serum CTGF/CCN2 levels will be evaluated, and their associations with clinical and ultrasonographic characteristics will be assessed.
- Conditions
- Plantar Fasciitis
- Medical subject headings
- Fasciitis, Plantar
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Chronic Plantar Fasciitis Group | Patients with chronic plantar fasciitis diagnosed based on clinical and ultrasonographic evaluation. | |
| Control Group | Asymptomatic participants without clinical or ultrasonographic findings of plantar fasciitis. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum CTGF/CCN2 Level
Serum Connective Tissue Growth Factor (CTGF/CCN2) levels will be measured in patients with chronic plantar fasciitis and asymptomatic controls.
Measured: At baseline
Secondary outcomes (3)
Pain Severity
Pain severity will be assessed using a Visual Analog Scale (VAS), and its association with serum CTGF/CCN2 levels will be evaluated.
Measured: At baseline
Foot Function Index
Functional status will be assessed using the Foot Function Index (FFI), and its association with serum CTGF/CCN2 levels will be evaluated.
Measured: At baseline
Plantar Fascia Thickness
Plantar fascia thickness will be measured by musculoskeletal ultrasonography, and its association with serum CTGF/CCN2 levels will be evaluated.
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2026
- Study start30 Aug 2026 (estimated)
- Primary completion30 Oct 2026 (estimated)
- Study completion15 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Plantar FasciitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zeynep Karakuzu Güngör, Kanuni Sultan Suleyman Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07785453
- Sponsor's protocol ID
- PF-CTGF-2026-01
- Status last verified
- Aug 2026
- First submitted
- 21 Aug 2026
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Serum Connective Tissue Growth Factor (CTGF/CCN2) Levels With Pain and Functional Status in Patients With Chronic Plantar Fasciitis
- ClinicalTrials.gov ID
- NCT07785453
- Acronym / sponsor ID
- PF-CTGF-2026-01
- Conditions
- Plantar Fasciitis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Kanuni Sultan Suleyman Training and Research HospitalUniversity, hospital or other
- Study start
- 30 Aug 2026 (estimated)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 15 Nov 2026 (estimated)
- First posted
- 25 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study aims to evaluate serum Connective Tissue Growth Factor (CTGF/CCN2) levels in patients with chronic plantar fasciitis compared with asymptomatic controls. The study will also assess the associations between serum CTGF levels and clinical and ultrasonographic characteristics of chronic plantar fasciitis.
Detailed description
This is a single-center observational study including patients with chronic plantar fasciitis and asymptomatic controls. Serum CTGF/CCN2 levels will be evaluated, and their associations with clinical and ultrasonographic characteristics will be assessed.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Chronic Plantar Fasciitis Group | – | –Patients with chronic plantar fasciitis diagnosed based on clinical and ultrasonographic evaluation. |
| Control Group | – | –Asymptomatic participants without clinical or ultrasonographic findings of plantar fasciitis. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged 18-65 years, including patients with chronic plantar fasciitis and asymptomatic controls without clinical or ultrasonographic findings of plantar fasciitis.
Key inclusion criteria (4 listed)
- Age 18-65 years.
- Written informed consent.
- For the patient group: chronic plantar heel pain for at least 3 months, pain during the first steps in the morning or after prolonged rest, tenderness over the medial calcaneal tubercle, and clinical and ultrasonographic findings consistent with chronic plantar fasciitis.
- For the control group: asymptomatic individuals without a previous diagnosis or clinical and ultrasonographic findings of plantar fasciitis.
Key exclusion criteria (10 listed)
- Tarsal tunnel syndrome, calcaneal stress fracture, plantar fascia rupture, Achilles tendinopathy, heel fat pad syndrome, plantar fibromatosis, or other foot conditions causing plantar heel pain.
- Diabetes mellitus.
- Inflammatory rheumatic diseases or gout.
- Chronic kidney or liver disease.
- Malignancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Serum CTGF/CCN2 Level
Time frame: At baseline
Serum Connective Tissue Growth Factor (CTGF/CCN2) levels will be measured in patients with chronic plantar fasciitis and asymptomatic controls.
3 secondary outcomes
Pain Severity
Time frame: At baseline
Foot Function Index
Time frame: At baseline
Plantar Fascia Thickness
Time frame: At baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Plantar Fasciitis
Not yet recruiting
Efficacy of TECAR Therapy in Plantar Fasciitis
Plantar Fasciitis
Active, not recruiting
Active Release Technique vs. Dynamic Soft Tissue Mobilization for Plantar Pain
Plantar Fascitis
Not yet recruiting
Hip Muscle Strengthening and Calf Myofascial Release in Females With Chronic Plantar Fasciitis
Chronic Planter Fascitis
Recruiting
F-18 Sodium Fluoride PET/CT-Guided Pain Palliation in Chronic Plantar Fasciitis: A Comparative Study of ¹⁷⁷Lutetium-Corticosteroid-Local Anaesthetic Injection vs Corticosteroid-Local Anaesthetic Injection
Plantar Fascitis, Chronic Heel Pain
Not yet recruiting
Radial vs Focused Shockwave Therapy for Plantar Fasciitis
Plantar Fasciitis, Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Plantar Fasciitis, run by Kanuni Sultan Suleyman Training and Research Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum CTGF/CCN2 Level (time frame: At baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.